triazolam has been researched along with Colitis, Ulcerative in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Colitis, Ulcerative: Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kusunoki, Y | 1 |
| Ikarashi, N | 1 |
| Hayakawa, Y | 1 |
| Ishii, M | 1 |
| Kon, R | 1 |
| Ochiai, W | 1 |
| Machida, Y | 1 |
| Sugiyama, K | 1 |
1 other study available for triazolam and Colitis, Ulcerative
| Article | Year |
|---|---|
Hepatic early inflammation induces downregulation of hepatic cytochrome P450 expression and metabolic activity in the dextran sulfate sodium-induced murine colitis.
Topics: Animals; Cell Nucleus; Colitis, Ulcerative; Constitutive Androstane Receptor; Cytochrome P-450 Enzym | 2014 |